Literature DB >> 27150160

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.

Lauren L Ritterhouse1, Jonathan A Nowak1, Kyle C Strickland1, Elizabeth P Garcia2, Yonghui Jia2, Neal I Lindeman1,2, Laura E Macconaill2, Panagiotis A Konstantinopoulos3, Ursula A Matulonis3, Joyce Liu3, Ross S Berkowitz4, Marisa R Nucci5, Christopher P Crum5, Lynette M Sholl1,2, Brooke E Howitt1,5.   

Abstract

Extrauterine high-grade serous carcinomas can exhibit various histologic patterns including (1) classic architecture that is papillary, micropapillary and infiltrative and (2) solid, endometrioid, and transitional (ie, SET) patterns. Although the SET pattern has been associated with germline BRCA mutations, potential molecular underpinnings have not been fully investigated. DNA was isolated from 174 carcinomas of the fallopian tube, ovary, or peritoneum. Targeted next-generation sequencing was performed and single-nucleotide and copy number variants were correlated with morphologic subtype. Overall, 79% of tumors were classified as high-grade serous carcinoma (n=138), and the most common mutations in high-grade serous carcinomas were TP53 (94%), BRCA1 (25%), BRCA2 (11%), and ATM (7%). Among chemotherapy-naive high-grade serous carcinomas, 40 cases exhibited classic morphology and 40 cases had non-classic morphology (SET or ambiguous features). Mutations in homologous recombination pathways were seen across all tumor histotypes. High-grade serous carcinomas with homologous recombination mutations were six times more likely to be associated with non-classic histology (P=0.002) and were significantly more likely to be platinum sensitive and have improved progression-free survival (PFS) (P=0.007 and P=0.004, respectively). In a multivariate analysis adjusted for age, homologous recombination mutation status and increased copy number variants were independently associated with improved PFS (P=0.008 and P=0.005, respectively). These findings underscore the potential significance of variant morphologic patterns and comprehensive genomic analysis in high-grade serous carcinomas with potential implications for pathogenesis, as well as response to targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27150160     DOI: 10.1038/modpathol.2016.82

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Authors:  David S P Tan; Christian Rothermundt; Karen Thomas; Elizabeth Bancroft; Rosalind Eeles; Susan Shanley; Audrey Ardern-Jones; Andrew Norman; Stanley B Kaye; Martin E Gore
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

2.  Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'.

Authors:  C Blake Gilks; Blaise A Clarke; Guangming Han; Martin Köbel; Teri Longacre; W Glenn McCluggage; Jeff D Seidman; Patricia Shaw; Robert A Soslow
Journal:  Mod Pathol       Date:  2011-09       Impact factor: 7.842

3.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

4.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

Authors:  Y Ben David; A Chetrit; G Hirsh-Yechezkel; E Friedman; B D Beck; U Beller; G Ben-Baruch; A Fishman; H Levavi; F Lubin; J Menczer; B Piura; J P Struewing; B Modan
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.

Authors:  Robert A Soslow; Guangming Han; Kay J Park; Karuna Garg; Narciso Olvera; David R Spriggs; Noah D Kauff; Douglas A Levine
Journal:  Mod Pathol       Date:  2011-12-23       Impact factor: 7.842

6.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

7.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

8.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Authors:  Angela Chetrit; Galit Hirsh-Yechezkel; Yehuda Ben-David; Flora Lubin; Eitan Friedman; Siegal Sadetzki
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

9.  Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.

Authors:  Evelyn Despierre; Matthieu Moisse; Betül Yesilyurt; Jalid Sehouli; Ioana Braicu; Sven Mahner; Dan Cacsire Castillo-Tong; Robert Zeillinger; Sandrina Lambrechts; Karin Leunen; Frédéric Amant; Philippe Moerman; Diether Lambrechts; Ignace Vergote
Journal:  Gynecol Oncol       Date:  2014-10-02       Impact factor: 5.482

10.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

View more
  6 in total

Review 1.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

Review 2.  Serous tubal intraepithelial neoplasia: the concept and its application.

Authors:  Emily E K Meserve; Jan Brouwer; Christopher P Crum
Journal:  Mod Pathol       Date:  2017-01-20       Impact factor: 7.842

3.  Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk.

Authors:  Elena Tenedini; Simonetta Piana; Angela Toss; Marco Marino; Elena Barbieri; Lucia Artuso; Marta Venturelli; Elisa Gasparini; Vincenzo Dario Mandato; Isabella Marchi; Sara Castellano; Mario Luppi; Tommaso Trenti; Laura Cortesi; Enrico Tagliafico
Journal:  JCO Precis Oncol       Date:  2022-08

4.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

5.  Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.

Authors:  Douglas I Lin; Jonathan K Killian; Jeffrey M Venstrom; Shakti H Ramkissoon; Jeffrey S Ross; Julia A Elvin
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

6.  Artificial intelligence-based image analysis can predict outcome in high-grade serous carcinoma via histology alone.

Authors:  Anna Ray Laury; Sami Blom; Tuomas Ropponen; Anni Virtanen; Olli Mikael Carpén
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.